TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05456620

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Description: The intervention treatment consists of a progressive 4-stage, criteria-based exercise protocol, in which the amount of tendon compression is limited. This includes:~1. Education: Specific information on the importance of limiting tendon compression during rehabilitation, as well as general information on load management, the importance of active exercise therapy and setting expectations.~2. Orthotic treatment: heel inserts to reduce ankle dorsiflexion during daily activities and sports~3. Physiotherapy: Progressive tendon-loading exercise therapy (4 phases) restricting the amount of tendon compression by limiting dorsiflexion of the ankle and prohibiting stretching

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise therapy (usual care)
Description: The control treatment consists of a progressive 4-phase, criteria-based exercise protocol, in which the amount of tendon compression is not limited. This includes:~1. Education: general information on load management, the importance of active exercise therapy and setting expectations.~2. No orthotic treatment.~3. Physiotherapy: Progressive tendon-loading exercise therapy (4 phases) without any restriction around tendon compression and encouraging stretching
Study: NCT02909374

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance training
Description: The balance-training program was developed based on well-established principles of exercise and on the knowledge that balance control relies on the interaction of several physiological systems, as well as interaction with environmental factors and the performed task. It includes exercise with dual- and multi task performance. It is progressive as the exercises can be performed at different levels (basic, moderate, and advanced), making it progressively challenging for each individual throughout the whole program. The training is conducted as an individually tailored group program.
Study: NCT04663646

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optokinetic stimulation
Description: Participants are placed in a standing position, with support products, if necessary, and virtual reality glasses will be placed where the visual stimuli will be projected.~The study will be carried out for 10 weeks with a frequency of two weekly sessions. During them, the participants will receive stimulation with OKS.~Stimulation will be performed at 1 cm/second, the vertical black bars will move to the left. The bars change color and the participants will be asked to detect the changes that will occur in the stimulus.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants are placed in a standing position, with support products, if necessary, and virtual reality glasses will be placed where the visual stimuli will be projected. In this group, stimulation consists of a video with static vertical bars that change their colour at a randon intervals, in the same way that in the intervention group. The difference between groups is that in control group, bars are not in movement, preventing from generating optokinetic stimulation.
Study: NCT04557501

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PSMA PET/CT guided intensification of therapy
Description: PSMA PET/CT prior to treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Arm
Description: Control - Treatment without PSMA PET/CT
Study: NCT06169410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel, lobaplatin, and S-1 combined with ramucirumab
Description: Patients in Experimental group will be given ramucirumab (8mg/kg) by intravenous drip on the first day of each cycle, 3 weeks a cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-paclitaxel, lobaplatin, and S-1
Description: Patients will be given lobaplatin (30 mg/m2) and nab-paclitaxel (100mg/m2) by intravenous drip on the first day of each cycle, 3 weeks a cycle, together with oral S-1 (patients with a body surface area less than 1.25 m2, will give 40 mg each time. Patients with a body surface area between 1.25 and 1.5 m2; will give 50 mg each time; patients with a body surface area greater than 1.5 m2, will give 60 mg each time), 2 weeks on and 1 week off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel, lobaplatin, and S-1
Description: Patients will be given lobaplatin (30 mg/m2) and nab-paclitaxel (100mg/m2) by intravenous drip on the first day of each cycle, 3 weeks a cycle, together with oral S-1 (patients with a body surface area less than 1.25 m2, will give 40 mg each time. Patients with a body surface area between 1.25 and 1.5 m2; will give 50 mg each time; patients with a body surface area greater than 1.5 m2, will give 60 mg each time), 2 weeks on and 1 week off.
Study: NCT05987163

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GP0116
Description: GP0116 is an injectable, sterile, transparent product.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: FDA approved dermal filler device
Description: FDA approved dermal filler device
Study: NCT05604976

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention
Description: Primary PCI for ST elevation myocardial infarction initiating with a universal guiding catheter or an angiographic catheter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Description: Primary PCI for ST elevation myocardial infarction initiating with a universal guiding catheter or an angiographic catheter
Study: NCT04893174

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UMC119-06-05
Description: Subjects will receive a single-dose IA injection of UMC119-06-05 followed by an IA injection of hyaluronic acid.~Cohort 1: Low does UMC119-06-05 Cohort 2: High does UMC119-06-05
Study: NCT01992263

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D (600 IU)
Description: Daily oral dose for 12 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D (2000 IU)
Description: Daily oral dose for 12 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D (4000 IU)
Description: Daily oral dose for 12 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily oral dose for 12 months
Study: NCT05832489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients will have 2 imaging sessions (MRI and EEG) after either:~* methylphenidate immediate release 25 mg~* placebo~in a cross-over design. The two imaging sessions will be separated by 11 to 87 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients will have 2 imaging sessions (MRI and EEG) after either:~* methylphenidate immediate release 25 mg~* placebo~in a cross-over design. The two imaging sessions will be separated by 11 to 87 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients will have 2 imaging sessions (MRI and EEG) after either:~* methylphenidate immediate release 25 mg~* placebo~in a cross-over design. The two imaging sessions will be separated by 11 to 87 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate immediate release 25mg
Description: Patients will have 2 imaging sessions (MRI and EEG) after either:~* methylphenidate immediate release 25 mg~* placebo~in a cross-over design. The two imaging sessions will be separated by 11 to 87 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate immediate release 25mg
Description: Patients will have 2 imaging sessions (MRI and EEG) after either:~* methylphenidate immediate release 25 mg~* placebo~in a cross-over design. The two imaging sessions will be separated by 11 to 87 days.
Study: NCT06571188

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: THORACIC EPIDURAL BLOCK
Description: In group TEB, The epidural catheter will be inserted preoperatively at the T5-T7 vertebral level; the exact level will be at the discretion of the attending anaesthesiologist. A loading dose of bupivacaine 0.25% (max 10 ml) will be administered, followed by an intraoperative infusion of bupivacaine 0.125 % with fentanyl 1 μg/ml.\].

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ERECTOER SPINE BLOCK
Description: The ESP block will be performed as described by Forero et al
Study: NCT06287346

Intervention type: DEVICE
Intervention: dental implant
Description: ceramic dental implant

Intervention type: DEVICE
Intervention: dental implant
Description: ceramic dental implant
Study: NCT05410327

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chokeberry (Aronia melanocarpa) juice
Description: A water-infused chokeberry (Aronia melanocarpa) juice will be used as the intervention. The brand being used is called 'Superberries'.
Study: NCT05017194

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emodepside
Description: Treatment with ascending doses of emodepside (from 5 mg to 30 mg) or albendazole (400 mg) or placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emodepside
Description: Treatment with ascending doses of emodepside (from 5 mg to 30 mg) or albendazole (400 mg) or placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emodepside
Description: Treatment with ascending doses of emodepside (from 5 mg to 30 mg) or albendazole (400 mg) or placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emodepside
Description: Treatment with ascending doses of emodepside (from 5 mg to 30 mg) or albendazole (400 mg) or placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emodepside
Description: Treatment with ascending doses of emodepside (from 5 mg to 30 mg) or albendazole (400 mg) or placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emodepside
Description: Treatment with ascending doses of emodepside (from 5 mg to 30 mg) or albendazole (400 mg) or placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emodepside
Description: Treatment with ascending doses of emodepside (from 5 mg to 30 mg) or albendazole (400 mg) or placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Emodepside
Description: Treatment with ascending doses of emodepside (from 5 mg to 30 mg) or albendazole (400 mg) or placebo.
Study: NCT05983718

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgical Guide
Description: For this case, after the patient is given anesthesia, the guide will be placed on the teeth. All the drillings will be performed through the guided path. There will be no need for raising flap according to flapless surgery. At the end of the operation, the operation site will be checked and hemostasis will be provided. The operator will record the operation in the source documentation. 2 ± 1 days later, a postoperative CT scan will be taken. A follow-up visit will be due 14 ± 2 weeks later, after the osseointegration period.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Guide-pin-assisted Freehand surgery
Description: The regular protocol of the implant surgery will be followed. Before the surgery begins, the patient will be given anesthesia to ensure they are comfortable and pain-free during the procedure. Doctors will go through the digital planning to understand the desired angulation. Then the bony bed will be prepared raising flap from targeted area. Then a guide-pin will be inserted by drilling and through radiographic image the direction will be confirmed. Following the hole of the guide-pin, the implant will be inserted. At the end of the operation, the raised flap will be sewn and hemostasis will be provided. The operator records the operation in the source documentation. 2 ± 1 days later, a postoperative CT scan will be taken. A follow-up visit will be due 14 ± 2 weeks later, after the osseointegration period.
Study: NCT06183359

Intervention type: OTHER
Group type: OTHER
Intervention: SIP
Description: compare the SIP group versus the ACT group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SIP
Description: compare the SIP group versus the ACT group
Study: NCT06116331

Intervention type: OTHER
Intervention: Data collection
Description: Participants will answer questionnaires and submit stool samples.
Study: NCT04963582

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: LI4 is located on the dorsum of the hand, midway between the 1st and 2nd metacarpal bones, approximately in the middle of the 2nd metacarpal bone on the radial side. Acupuncture is practiced by using 0,25x25mm sized needles. LI4 point is punctured perpendicularly 2cm in the direction of the palm center.
Study: NCT04893174

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Description: IA injection of hyaluronic acid.
Study: NCT04831957

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Assesment of thyroïd function
Description: Blood sample for TSH, fT4, fT3, anti TPO, anti TG thyroid ultra sound Iodine urine sample
Study: NCT05325502

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: caffeine
Description: two doses per day: 200 mg caffeine in the morning; 100 mg caffeine in the afternoon

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: caffeine
Description: two doses per day: 200 mg caffeine in the morning; 100 mg caffeine in the afternoon

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: mannitol
Description: two doses per day: 200 mg in the morning \& 100 mg in the afternoon

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: mannitol
Description: two doses per day: 200 mg in the morning \& 100 mg in the afternoon
Study: NCT06101381

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-19
Description: The academic CART-19 consists of autologous T lymphocytes transduced with a lentiviral vector to express a second-generation chimeric antigen receptor with a single chain variable fragment (scFv) targeting the CD19 antigen conjugated with 4-1BB co-stimulatory and CD3z signaling domains.
Study: NCT05596695

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Minimizing blood pressure variability
Description: Intraoperative blood pressure management will be performed to maintain a systolic blood pressure of 120 ±5mmHg using a continuous infusion of a vasopressor starting at induction of anaesthesia.
Study: NCT05659875

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Occupational Therapy Arm Exercise Program
Description: Standard exercise program will be provided addressing shoulder, elbow, forearm, wrist, and hand with expectation that participant will complete 3 times a week. Exercise program will be updated at assessment timepoints as needed with change in arm function.
Study: NCT06508593

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum metabolic profile
Description: Venous serum samples were analyzed for serum metabolic profiles using liquid chromatography-mass spectrometry (LC-MS) and gas chromatography-mass spectrometry (GC-MS) non targeted metabolomics techniques

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum metabolic profile
Description: Venous serum samples were analyzed for serum metabolic profiles using liquid chromatography-mass spectrometry (LC-MS) and gas chromatography-mass spectrometry (GC-MS) non targeted metabolomics techniques

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum metabolic profile
Description: Venous serum samples were analyzed for serum metabolic profiles using liquid chromatography-mass spectrometry (LC-MS) and gas chromatography-mass spectrometry (GC-MS) non targeted metabolomics techniques

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum metabolic profile
Description: Venous serum samples were analyzed for serum metabolic profiles using liquid chromatography-mass spectrometry (LC-MS) and gas chromatography-mass spectrometry (GC-MS) non targeted metabolomics techniques
Study: NCT04462328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be administered over 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be administered over 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be administered over 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Patients will take acalabrutinib orally every 12 hours (+/- 3 hours) daily.
Study: NCT05013983

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 vaccine (Sf9 cells)
Description: This vaccine is made by using baculovirus as a vector and expressing SARS-CoV-2 S-RBD in Sf9 cells, which is purified
Study: NCT04462328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Patients will take acalabrutinib orally every 12 hours (+/- 3 hours) daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Patients will take acalabrutinib orally every 12 hours (+/- 3 hours) daily.
Study: NCT05013983

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 vaccine (Sf9 cells)
Description: This vaccine is made by using baculovirus as a vector and expressing SARS-CoV-2 S-RBD in Sf9 cells, which is purified

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 vaccine (Sf9 cells)
Description: This vaccine is made by using baculovirus as a vector and expressing SARS-CoV-2 S-RBD in Sf9 cells, which is purified

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 vaccine (Sf9 cells)
Description: This vaccine is made by using baculovirus as a vector and expressing SARS-CoV-2 S-RBD in Sf9 cells, which is purified

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Except for the absence of study vaccine antigen, all other components (aluminum hydroxide, sodium chloride, sodium

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Except for the absence of study vaccine antigen, all other components (aluminum hydroxide, sodium chloride, sodium
Study: NCT05489432

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A twelve-week prehabilitation program consisting of physical exercises, nutritional measures and psychosocial interventions based on the KTCs personal needs as indicated by an assessment consisting of questionnaires and physical tests. The prehabilitation program will be followed by a twelve-week consolidation program, in which the intensity and frequency of the interventions will be lower, in order to enhance the incorporation of the interventions into the daily life of the KTC. During the intervention period, participants will receive counseling by a lifestyle coach.
Study: NCT05013983

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Except for the absence of study vaccine antigen, all other components (aluminum hydroxide, sodium chloride, sodium

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Except for the absence of study vaccine antigen, all other components (aluminum hydroxide, sodium chloride, sodium
Study: NCT04544592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells
Description: The CD19 CAR used in this study consists of three main components: the variable regions of the anti-CD19 monoclonal antibody FMC63 71, linked to the TNFRSF19-derived transmembrane domain, the 4-1BB costimulatory molecule, and the signaling domain of the CD3-zeta molecule. The DNA encoding this receptor was cloned into a lentiviral vector (LV) backbone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells
Description: The CD19 CAR used in this study consists of three main components: the variable regions of the anti-CD19 monoclonal antibody FMC63 71, linked to the TNFRSF19-derived transmembrane domain, the 4-1BB costimulatory molecule, and the signaling domain of the CD3-zeta molecule. The DNA encoding this receptor was cloned into a lentiviral vector (LV) backbone.
Study: NCT04398160

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HVLA C3/C4 manipulation
Description: The investigator will apply an anterior and lateral translation associated with extension, homolateral inclination and contralateral rotation of the cervical. This procedure will increase the tension of the soft tissues to reduce the remaining slack and, finally, the thrust will be applied in pure rotation. Subsequently the head of the volunteer will be repositioned in the neutral position without applying any pressure and will wait 10 seconds in this position. Finally, the previous procedure will be repeated to the opposite side.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham technique
Description: The investigator will apply an anterior and lateral translation associated with extension, homolateral inclination and contralateral rotation of the cervical until the perception of tissue tension at the point of contact, holding this position for 10 seconds. The investigator then repositions the head of the volunteer in the neutral position without applying pressure, holding again this position for 10 seconds. Finally, the previous procedure will be repeated for the opposite side.
Study: NCT04969653

Intervention type: OTHER
Intervention: Exposure of venous thromboembolism
Description: Composite of pulmonary embolism and deep vein thrombosis

Intervention type: OTHER
Intervention: Exposure of venous thromboembolism
Description: Composite of pulmonary embolism and deep vein thrombosis
Study: NCT05691530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rDENdelta30/31-7164
Description: The rDEN3delta30/31-7164 vaccine is a live attenuated virus constructed by creating two deletions in the 3 UTR of the DENV3 Sleman/78 strain. The rDEN3delta30/31-7164 vaccine will be delivered subcutaneously into the left deltoid area on day 0. The vaccine dose will consist of 0.5 mL of 10\^3 PFU/mL of rDEN3delta30/31-7164 plus Plasma-Lyte A pH 7.4 diluent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rDENdelta30/31-7164
Description: The rDEN3delta30/31-7164 vaccine is a live attenuated virus constructed by creating two deletions in the 3 UTR of the DENV3 Sleman/78 strain. The rDEN3delta30/31-7164 vaccine will be delivered subcutaneously into the left deltoid area on day 0. The vaccine dose will consist of 0.5 mL of 10\^3 PFU/mL of rDEN3delta30/31-7164 plus Plasma-Lyte A pH 7.4 diluent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rDENdelta30/31-7164
Description: The rDEN3delta30/31-7164 vaccine is a live attenuated virus constructed by creating two deletions in the 3 UTR of the DENV3 Sleman/78 strain. The rDEN3delta30/31-7164 vaccine will be delivered subcutaneously into the left deltoid area on day 0. The vaccine dose will consist of 0.5 mL of 10\^3 PFU/mL of rDEN3delta30/31-7164 plus Plasma-Lyte A pH 7.4 diluent.